Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
More >>
Select Topic:
Browse by Series:

PD-1 Inhibitors in NSCLC: Combination or Monotherapy

Panelists: David R. Gandara, MD, UC Davis Comprehensive Cancer Center; Everett E. Vokes, MD, University of Chicago Medicine
Published: Tuesday, Nov 20, 2018



Transcript:

SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript:
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
x